Dr. Adam Rogers reports

NERVGEN PHARMA BEGINS TRADING ON NASDAQ TODAY

Nervgen Pharma Corp.'s common shares have been approved for listing on Nasdaq. Nervgen's common shares will begin trading on Nasdaq today, under the symbol NGEN.

"A listing on Nasdaq marks a defining moment in Nervgen's evolution as a leading biopharmaceutical company developing neuroreparative therapeutics," said Adam Rogers, MD, interim chief executive officer of Nervgen Pharma. "With unprecedented phase 1b/2a Connect SCI data demonstrating durable improvements in function, independence and quality of life in chronic SCI, we are entering late-stage development from a position of clinical and organizational strength. We believe this listing will enhance visibility in the marketplace, improve liquidity, broaden and diversify our shareholder base, and ultimately drive long-term shareholder value as we advance NVG-291 toward potentially becoming the first approved pharmacologic therapy for SCI and transforming the treatment paradigm for neurotraumatic and neurologic conditions with significant unmet medical need."

Nervgen's listing on Nasdaq follows the company's announcement of expanded phase 1b/2a Connect SCI Study data on Nov. 24, 2025, in which NVG-291 demonstrated unprecedented durable improvement in function, independence and quality of life in individuals with chronic SCI between one to 10 years postinjury. NVG-291's ability to enable the nervous system to repair itself is supported by statistically significant improvements in upper-limb corticospinal signaling, as well as statistically significant reductions in hyperactive upper and lower-limb reticulospinal signaling. Nervgen will conduct a United States Food and Drug Administration (FDA) end-of-phase-2 meeting in early 2026 to align on the development and registration pathway for NVG-291. In September, 2025, the company completed an FDA Type C meeting, during which the FDA confirmed that multiple regulatory pathways are available to support approval.

About Nervgen Pharma Corp.

Nervgen Pharma is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. The company's mission is to transform the lives of individuals living with SCI by enabling the nervous system to repair itself. Nervgen's lead therapeutic candidate, NVG-291, is a subcutaneously administered, neuroreparative peptide. NVG-291 was evaluated in the phase 1b/2a Connect SCI study in individuals with chronic SCI between one to 10 years postinjury and is the first pharmacologic candidate to demonstrate durable improvement in function, independence and quality of life. Enrolment of individuals with subacute SCI in the phase 1b/2a Connect SCI study is continuing, alongside preparation for a phase 3 clinical trial in chronic SCI. NVG-291 has received fast-track designation from the FDA and orphan drug designation from the European Medicines Agency (EMA) for the treatment of SCI. Through NVG-291 and the company's next-generation candidate, NVG-300, Nervgen is pursuing a pharmacologic approach to transform the treatment paradigm for neurotraumatic and neurologic conditions with significant unmet medical need.

We seek Safe Harbor.